Please login to the form below

tafamidis

This page shows the latest tafamidis news and features for those working in and with pharma, biotech and healthcare.

Pfizer buys dwarfism drug company Therachon for $810m

The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)

Latest news

Speedy approval for Pfizer's Onpattro rival

Approved in two different formulations. Pfizer’s blockbuster-in-waiting drug tafamidis has gained FDA approval to treat cardiomyopathy in patients with rare disease ATTR. ... Pfizer filed the drug in two oral formulations, one known as Vyndaqel
Solid Q1 results lift Pfizer as it waits for pipeline boost

That will come on the back of product launches like tafamidis in rare disease transthyretin amyloid cardiomyopathy, a trio of recently-approved cancer drugs including Vizimpro (dacomitinib), a rival to
Alnylam gets EU nod for Onpattro amid pricing backlash

s Vyndaqel (tafamidis) has been registered in Europe since 2011 and costs in the region of $13, 000 per month. ... for tafamidis as a treatment for cardiomyopathy associated with hATTR amyloidosis after reporting positive results in the phase III
Alnylam claims RNAi milestone with Onpattro approval

approved for that indication by the EMA in July and Pfizer’s Vyndaqel (tafamidis) which has been on the market since 2011 but was rejected by the FDA in 2012.
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

The EMA said in a statement that having two drugs “considerably widens” the therapeutic options for hATTR amyloidosis, which include liver transplant, Pfizer’s Vyndaqel (tafamidis) and off-label non-steroidal

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

produced impressive data for its Vyndaqel (tafamidis). ... Onpattro looked to have the edge in terms of clinical data, but Pfizer has new data showing tafamidis is effective in treating patients with cardiomyopathy – the heart damage caused by the
Tough times for pharma in Portugal

spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Director – UK Office: Excellent salary and benefits

Account Manager – Healthcare advertising: Salary TBC

Senior Medical Writer: Competitive salary plus benefits

Client Services Director- Flexible Working: Negotiable

Events Executive: DOE

Subscribe to our email news alerts

PMHub

Add my company

CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...